Solvonis Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
SVNS
- Investments
-
1
Solvonis Therapeutics General Information
Description
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Contact Information
Website
www.solvonis.comCorporate Office
- 25 Eccleston Place
- London SW1W 9NF
- England, United Kingdom
Corporate Office
- 25 Eccleston Place
- London SW1W 9NF
- England, United Kingdom
Solvonis Therapeutics Timeline
Solvonis Therapeutics Stock Performance
As of 13-Nov-2026, Solvonis Therapeutics’s current market cap is $9.4M with 7.9B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.4M | 7.9B | 34.9M |
Solvonis Therapeutics Financials Summary
As of 30-Jun-2026, Solvonis Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 13,606 | 26,202 | 6,203 | 151 |
| Revenue | 0 | 0 | 0 | 730 |
| EBITDA | (3,655) | |||
| Net Income | (7,455) | (7,561) | (2,032) | (3,878) |
| Total Assets | 8,518 | 10,214 | 4,019 | 3,101 |
| Total Debt | 95 | 101 | 0 | 43 |
Solvonis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Solvonis Therapeutics Signals
Solvonis Therapeutics Acquisitions (1)
Solvonis Therapeutics’s most recent deal was a Merger/Acquisition with Awakn Life Sciences for . The deal was made on 27-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Awakn Life Sciences | 27-May-2025 | Merger/Acquisition | Biotechnology |
Solvonis Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Machinery
Industry
Rank
Percentile
Industrial Machinery
Subindustry
Rank
Percentile
Solvonis Therapeutics FAQs
-
When was Solvonis Therapeutics founded?
Solvonis Therapeutics was founded in 2017.
-
Where is Solvonis Therapeutics headquartered?
Solvonis Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Solvonis Therapeutics?
Solvonis Therapeutics has 6 total employees.
-
What industry is Solvonis Therapeutics in?
Solvonis Therapeutics’s primary industry is Drug Discovery.
-
Is Solvonis Therapeutics a private or public company?
Solvonis Therapeutics is a Public company.
-
What is Solvonis Therapeutics’s stock symbol?
The ticker symbol for Solvonis Therapeutics is SVNS.
-
What is the current market cap of Solvonis Therapeutics?
The current market capitalization of Solvonis Therapeutics is $9.4M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process